Drugs / etaracizumab
etaracizumab
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT00111696 | May 2005 → Aug 2007 | melanoma | MedImmune LLC | Completed | No outcome recorded |
| Phase 1 | NCT00049712 | Oct 2002 → Feb 2006 | lymphoma, small intestine cancer | University of Wisconsin, Madison | Completed | No outcome recorded |
| Phase 1 | NCT00263783 | Mar 2001 → Apr 2002 | cancer | MedImmune LLC | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT00284817 | Jul 2001 → Jan 2005 | cancer | MedImmune LLC | Completed | No outcome recorded |
| Phase 1/2 | NCT00027729 | Jun 2001 → Nov 2004 | colorectal cancer | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
Also used as a comparator or background therapy in 5 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00684996 Comparator | Jun 2008 → Oct 2010 | renal cell carcinoma | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT00072930 Comparator | Dec 2003 → Apr 2007 | prostate cancer | MedImmune LLC | Completed | No outcome recorded |
| Phase 2 | NCT00192517 Comparator | Dec 2003 → Aug 2004 | psoriasis | MedImmune LLC | Completed | No outcome recorded |
| Phase 2 | NCT00069017 Comparator | Sep 2003 → Apr 2006 | rheumatoid arthritis | MedImmune LLC | Completed | No outcome recorded |
| Phase 2 | NCT00066196 Comparator | Aug 2003 → Apr 2007 | metastatic melanoma | MedImmune LLC | Completed | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | etaracizumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00027729 ↗ |
| Known as | Abegrin | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314357 ↗ |
| Known as | Abegrin vitaxin | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314357 ↗ |
| Known as | Abergrin | “Phase I Study of the Tumor Saturation and Biological Activity of MEDI-522 (Abergrin), a Humanized Monoclonal Antibody Directed Against the Human Alpha V Beta 3 Integrin, in...” NCT00111696 ↗ |
| Known as | ETARATUZUMAB | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314357 ↗ |
| Known as | HLM60 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314357 ↗ |
| Known as | MEDI522 | “Phase I Study of MEDI522, a Humanized Monoclonal Antibody Directed Against the Human Alpha V Beta 3 Integrin, in Patients With Irinotecan-Refractory Advanced Colorectal Cancer...” NCT00284817 ↗7“IV administration supplied in 10 mL vials containing 100 mg of MEDI-522 at a concentration of 10 mg/mL.” NCT00066196 ↗ |
| Known as | Vitaxin | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314357 ↗ |
| Modality | Monoclonal antibody | “Humanized Monoclonal Antibody” NCT00027729 ↗ |
| Route | Intravenous | “Patients receive monoclonal antibody anti-anb3 integrin IV over 30 minutes once weekly” NCT00027729 ↗ |